Marianne Romeo - Myovant Sciences Head, Global Transactions & Risk Management
| MYOVDelisted Stock | USD 26.98 0.01 0.04% |
Executive
Ms. Marianne L. Romeo is a Head, Global Transactions Risk Management of the Company. Ms. Romeo has served as Head, Global Transactions Risk Management of Roivant Sciences Ltd. since October 2014 and Axovant Sciences Ltd. since March 2015. Previously, Ms. Romeo had a 20 year career with Marsh Inc. in risk consulting and insurance brokerage, most recently serving as Managing Director and Head of Casualty from 2008 to 2014 and Senior Vice President and Healthcare Practice Leader from 2003 to 2008 for Bowring Marsh Ltd., an international insurance placement broker and wholly owned subsidiary of Marsh Inc. During her time at Bowring Marsh, Ms. Romeo served in various functional roles, including excess casualty brokerage, risk management consulting, and business management. Ms. Romeo established the Healthcare Practice within Marshs Bermuda operation in 2003 and continues to serve on the Board of the Bermuda Society for Healthcare Risk Management . Ms. Romeo has served on the board of directors of Axovant Sciences Ltd. since March 2015 since 2016.
| Age | 49 |
| Tenure | 8 years |
| Phone | 44 20 7400 3351 |
| Web | https://myovant.com |
Myovant Sciences Management Efficiency
The company has return on total asset (ROA) of (0.1822) % which means that it has lost $0.1822 on every $100 spent on assets. This is way below average. Myovant Sciences' management efficiency ratios could be used to measure how well Myovant Sciences manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 358.7 M in liabilities with Debt to Equity (D/E) ratio of 138.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Myovant Sciences has a current ratio of 1.79, which is within standard range for the sector. Debt can assist Myovant Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Myovant Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Myovant Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Myovant to invest in growth at high rates of return. When we think about Myovant Sciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chris Allexandre | Renesas Electronics | 48 | |
| Robert Paver | Jabil Circuit | 58 | |
| Gili Brudno | Playtika Holding Corp | 50 | |
| Beth Walters | Jabil Circuit | 64 | |
| Manuel Becerra | Assurant | 60 | |
| Gregory DeChurch | Assurant | N/A | |
| Yoshikazu Yokota | Renesas Electronics | N/A | |
| Hiroto Nitta | Renesas Electronics | 63 | |
| Sean Moshier | Assurant | N/A | |
| Alecia Bailey | Assurant | N/A | |
| Megumi Nakano | Renesas Electronics | N/A | |
| Tomomitsu Maoka | Renesas Electronics | N/A | |
| Gerald Creadon | Jabil Circuit | 50 | |
| Frederic McCoy | Jabil Circuit | 56 | |
| Michael Esq | Playtika Holding Corp | 53 | |
| Kristine Melachrino | Jabil Circuit | 46 | |
| David Rubin | Flex | N/A | |
| Claude Sarfo | Assurant | N/A | |
| Michael Mendenhall | Flex | N/A | |
| Darlan Monterisi | Playtika Holding Corp | N/A | |
| Joseph III | Assurant | N/A | |
Management Performance
| Return On Asset | -0.18 |
Myovant Sciences Leadership Team
Elected by the shareholders, the Myovant Sciences' board of directors comprises two types of representatives: Myovant Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Myovant. The board's role is to monitor Myovant Sciences' management team and ensure that shareholders' interests are well served. Myovant Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Myovant Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Karbe, Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc. | ||
| Juan Ferreira, Chief Commercial Officer - Myovant Sciences, Inc | ||
| Mark Altmeyer, Independent Director | ||
| Nancy Valente, Director | ||
| Kim Sablich, Chief Commercial Officer | ||
| Adele Gulfo, Director, Interim Chief Commercial Officer | ||
| Myrtle Potter, Chairman of the Board | ||
| Terrie Curran, Independent Director | ||
| Lauren Merendino, Chief Commercial Officer | ||
| Keith Manchester, Director | ||
| Marianne Romeo, Head, Global Transactions & Risk Management | ||
| Ann Tomlin, VP HR | ||
| Juan MD, Chief Officer | ||
| Uneek Mehra, Chief Financial and Business Officer, Principal Financial and Accounting Officer | ||
| Frank Torti, Director | ||
| Andria MD, Head Pharmacovigilance | ||
| Matthew JD, Gen Sec | ||
| Vivek Ramaswamy, Director | ||
| Jeffrey Nornhold, Senior Vice President Pharmaceutical Operations & Development | ||
| Albert Liao, Director Communications | ||
| Wayne DeVeydt, Independent Director | ||
| Matthew Lang, General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc. | ||
| Kathleen Sebelius, Lead Independent Director | ||
| Mark Guinan, Independent Director | ||
| David Marek, Principal Executive Officer, Director | ||
| Hiroshi Nomura, Director | ||
| Bryan Selby, VP Devel | ||
| Lynn Seely, Principal Executive Officer, Director |
Myovant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Myovant Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.18 | |||
| Profit Margin | (0.48) % | |||
| Operating Margin | (0.39) % | |||
| Current Valuation | 2.6 B | |||
| Shares Outstanding | 97.26 M | |||
| Shares Owned By Insiders | 48.61 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Number Of Shares Shorted | 8.39 M | |||
| Price To Earning | (8.56) X | |||
| Price To Book | 70.01 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Myovant Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Myovant Sciences' short interest history, or implied volatility extrapolated from Myovant Sciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Myovant Stock
If you are still planning to invest in Myovant Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Myovant Sciences' history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |